patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_841134 | REC_0008801 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 16.8 | 73 | female | 1 | 14 | 6.2 | 2 | osimertinib 80 mg daily | 4 | false | MSI-H | 2026-03-15T05:35:59.021428+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_114952 | REC_0008802 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 20.6 | 72 | male | 1 | 16 | 6.4 | 4 | osimertinib 80 mg daily | 12.3 | true | MSS | 2026-03-15T05:35:59.021720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_697941 | REC_0008803 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 12.6 | 63 | male | 1 | 13 | 7.4 | 8 | osimertinib 80 mg daily | 9.2 | false | MSS | 2026-03-15T05:35:59.021960+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224242 | REC_0008804 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 10.7 | 79 | female | 1 | 16 | 6.7 | 6 | entrectinib 600 mg daily | 11 | false | MSS | 2026-03-15T05:35:59.022192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236015 | REC_0008805 | Non-small cell lung cancer | Large cell carcinoma | III | None (PD-L1 high) | 30 | 7.1 | 64 | male | 0 | 24 | 4.2 | 0 | pembrolizumab 200 mg q3w | 48.8 | true | MSS | 2026-03-15T05:35:59.022425+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_832114 | REC_0008806 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 14.1 | 77 | male | 2 | 23 | 6 | 2 | alectinib 600 mg BID | 8.9 | false | MSI-H | 2026-03-15T05:35:59.022664+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172436 | REC_0008807 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 5.8 | 77 | female | 2 | 37 | 5.5 | 6 | pembrolizumab 200 mg q3w | 15.3 | true | MSS | 2026-03-15T05:35:59.022893+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_872148 | REC_0008808 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 16.3 | 61 | male | 1 | 15 | 2.6 | 5 | sotorasib 960 mg daily | 16.9 | true | MSS | 2026-03-15T05:35:59.023132+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857866 | REC_0008809 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 11.5 | 68 | male | 0 | 10 | 6.7 | 5 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:59.023370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910208 | REC_0008810 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 4.5 | 55 | female | 0 | 21 | 7.5 | 1 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.023604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518342 | REC_0008811 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 11.9 | 74 | female | 1 | 21 | 7 | 1 | pembrolizumab 200 mg q3w | 24.9 | false | MSS | 2026-03-15T05:35:59.023836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_538232 | REC_0008812 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 10.6 | 65 | female | 1 | 15 | 4.3 | 1 | sotorasib 960 mg daily | 8.7 | false | MSI-H | 2026-03-15T05:35:59.024067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_990135 | REC_0008813 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 13.6 | 55 | male | 1 | 8 | 5.2 | 6 | sotorasib 960 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:59.024340+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_246053 | REC_0008814 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 3.5 | 71 | male | 2 | 25 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:59.024575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_837565 | REC_0008815 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 21 | 24.9 | 77 | female | 1 | 15 | 5.1 | 1 | sotorasib 960 mg daily | 24.5 | false | MSS | 2026-03-15T05:35:59.024854+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_715472 | REC_0008816 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 19.5 | 68 | male | 0 | 16 | 4.2 | 6 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.025093+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352007 | REC_0008817 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 12 | 58 | male | 1 | 14 | 5.9 | 2 | alectinib 600 mg BID | 14.3 | true | MSI-H | 2026-03-15T05:35:59.025329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394929 | REC_0008818 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 28 | 4.6 | 73 | female | 2 | 28 | 6.6 | 7 | pembrolizumab 200 mg q3w | 11 | false | MSS | 2026-03-15T05:35:59.025556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561584 | REC_0008819 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 14.4 | 77 | female | 1 | 8 | 5.9 | 2 | sotorasib 960 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:59.025792+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539648 | REC_0008820 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 10.4 | 69 | male | 1 | 13 | 3.4 | 6 | osimertinib 80 mg daily | 17.6 | false | MSI-H | 2026-03-15T05:35:59.026026+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_562915 | REC_0008821 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 19.6 | 59 | female | 1 | 17 | 5.3 | 3 | osimertinib 80 mg daily | 10.5 | false | MSS | 2026-03-15T05:35:59.026260+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_888749 | REC_0008822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 7.2 | 55 | female | 1 | 49 | 7.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.9 | false | MSS | 2026-03-15T05:35:59.026491+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673736 | REC_0008823 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 32 | 10.5 | 73 | female | 1 | 17 | 6.5 | 1 | sotorasib 960 mg daily | 18.7 | false | MSS | 2026-03-15T05:35:59.026724+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_812242 | REC_0008824 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 13.5 | 80 | male | 1 | 7 | 5.4 | 7 | sotorasib 960 mg daily | 9.1 | false | MSS | 2026-03-15T05:35:59.026964+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_281621 | REC_0008825 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 15 | 8.5 | 73 | male | 1 | 14 | 4.2 | 6 | osimertinib 80 mg daily | 8.7 | true | MSS | 2026-03-15T05:35:59.027196+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_857750 | REC_0008826 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 32 | 5.3 | 69 | female | 0 | 45 | 6.7 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSS | 2026-03-15T05:35:59.027427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_680824 | REC_0008827 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.4 | 82 | female | 1 | 20 | 5.6 | 5 | osimertinib 80 mg daily | 5.7 | true | MSS | 2026-03-15T05:35:59.027658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_644926 | REC_0008828 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 15 | 8 | 66 | female | 1 | 23 | 4.8 | 2 | pembrolizumab 200 mg q3w | 15.2 | true | MSS | 2026-03-15T05:35:59.027926+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_745559 | REC_0008829 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 29 | 10.4 | 62 | female | 0 | 31 | 7.8 | 1 | entrectinib 600 mg daily | 16.2 | true | MSS | 2026-03-15T05:35:59.028191+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_197778 | REC_0008830 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 20.2 | 60 | female | 0 | 10 | 6.6 | 2 | alectinib 600 mg BID | 17.9 | false | MSS | 2026-03-15T05:35:59.028432+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_466029 | REC_0008831 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 24 | 12.3 | 77 | female | 0 | 20 | 8 | 2 | sotorasib 960 mg daily | 22.6 | true | MSI-H | 2026-03-15T05:35:59.028669+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_406083 | REC_0008832 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 23 | 15.2 | 70 | female | 1 | 28 | 7 | 0 | entrectinib 600 mg daily | 60.3 | true | MSI-H | 2026-03-15T05:35:59.028903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514275 | REC_0008833 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 10.6 | 63 | female | 1 | 13 | 5.5 | 2 | osimertinib 80 mg daily | 13.8 | true | MSI-H | 2026-03-15T05:35:59.029138+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_514543 | REC_0008834 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7 | 68 | female | 0 | 27 | 6.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 6.9 | false | MSS | 2026-03-15T05:35:59.029370+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_778528 | REC_0008835 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 13.5 | 60 | female | 1 | 17 | 5 | 5 | alectinib 600 mg BID | 6.5 | true | MSS | 2026-03-15T05:35:59.029605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125381 | REC_0008836 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.7 | 71 | female | 1 | 15 | 3.4 | 2 | sotorasib 960 mg daily | 15.3 | true | MSS | 2026-03-15T05:35:59.029838+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_459632 | REC_0008837 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.7 | 63 | male | 1 | 6 | 6.2 | 6 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:59.030075+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842992 | REC_0008838 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 15.6 | 72 | female | 2 | 23 | 5.9 | 8 | pembrolizumab 200 mg q3w | 16 | false | MSI-H | 2026-03-15T05:35:59.030308+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537917 | REC_0008839 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 11.5 | 70 | female | 1 | 15 | 5.4 | 4 | osimertinib 80 mg daily | 4 | true | MSI-H | 2026-03-15T05:35:59.030539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571891 | REC_0008840 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 19 | 8.8 | 62 | male | 1 | 0 | 6.3 | 2 | alectinib 600 mg BID | 10.8 | true | MSS | 2026-03-15T05:35:59.030767+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_349793 | REC_0008841 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 33 | 9.1 | 70 | male | 2 | 5 | 4.9 | 2 | pembrolizumab 200 mg q3w | 18.3 | true | MSS | 2026-03-15T05:35:59.031039+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_736173 | REC_0008842 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 5.4 | 69 | female | 1 | 67 | 5 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.3 | true | MSS | 2026-03-15T05:35:59.031273+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_919889 | REC_0008843 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 15 | 6.9 | 65 | female | 0 | 7 | 5.6 | 3 | entrectinib 600 mg daily | 14 | true | MSS | 2026-03-15T05:35:59.031505+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394015 | REC_0008844 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 28 | 7.8 | 70 | female | 3 | 8 | 4.4 | 1 | alectinib 600 mg BID | 11.9 | false | MSS | 2026-03-15T05:35:59.031733+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_334186 | REC_0008845 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 16 | 12.3 | 77 | female | 1 | 16 | 5.1 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:59.031965+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124396 | REC_0008846 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 5.5 | 75 | female | 2 | 65 | 5 | 5 | pembrolizumab 200 mg q3w | 10 | false | MSS | 2026-03-15T05:35:59.032239+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207852 | REC_0008847 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 3.3 | 61 | female | 1 | 36 | 3.5 | 2 | carboplatin + paclitaxel + pembrolizumab | 29 | false | MSS | 2026-03-15T05:35:59.032489+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182330 | REC_0008848 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 11.9 | 78 | female | 1 | 16 | 6.7 | 8 | entrectinib 600 mg daily | 6.8 | false | MSI-H | 2026-03-15T05:35:59.032723+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161321 | REC_0008849 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 15.1 | 68 | female | 1 | 15 | 4.8 | 1 | entrectinib 600 mg daily | 21.3 | true | MSS | 2026-03-15T05:35:59.032957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_730396 | REC_0008850 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 12 | 81 | female | 0 | 19 | 6.2 | 7 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:59.033189+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_592780 | REC_0008851 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 20 | 11.7 | 68 | female | 1 | 17 | 4.3 | 5 | osimertinib 80 mg daily | 12.6 | false | MSI-H | 2026-03-15T05:35:59.033421+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_936156 | REC_0008852 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 20 | 13.5 | 78 | female | 2 | 9 | 6.5 | 6 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:59.033651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_671283 | REC_0008853 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 5.2 | 70 | female | 1 | 11 | 6.2 | 1 | osimertinib 80 mg daily | 22.3 | false | MSS | 2026-03-15T05:35:59.033886+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_336887 | REC_0008854 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 30 | 10 | 68 | female | 0 | 12 | 4.7 | 1 | entrectinib 600 mg daily | 23.4 | false | MSS | 2026-03-15T05:35:59.034161+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_929067 | REC_0008855 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 18.1 | 73 | female | 1 | 34 | 5.5 | 5 | osimertinib 80 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.034400+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_301732 | REC_0008856 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.5 | 64 | male | 1 | 16 | 7.8 | 1 | osimertinib 80 mg daily | 23.4 | true | MSI-H | 2026-03-15T05:35:59.034635+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_267435 | REC_0008857 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 3.6 | 74 | female | 1 | 54 | 5.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.1 | true | MSS | 2026-03-15T05:35:59.034865+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_482559 | REC_0008858 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 17 | 65 | male | 1 | 11 | 4.5 | 5 | sotorasib 960 mg daily | 16.2 | false | MSS | 2026-03-15T05:35:59.035099+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_244494 | REC_0008859 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 2.5 | 67 | female | 0 | 49 | 2.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 15.6 | false | MSS | 2026-03-15T05:35:59.035326+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495002 | REC_0008860 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 13.5 | 52 | male | 0 | 18 | 8.7 | 3 | osimertinib 80 mg daily | 23.7 | true | MSI-H | 2026-03-15T05:35:59.035560+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_306163 | REC_0008861 | Non-small cell lung cancer | Adenocarcinoma | III | KRAS G12C | 30 | 7.4 | 56 | female | 1 | 16 | 6.5 | 0 | sotorasib 960 mg daily | 42 | false | MSS | 2026-03-15T05:35:59.035793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788070 | REC_0008862 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 13.3 | 57 | male | 0 | 11 | 6.5 | 7 | osimertinib 80 mg daily | 17.3 | true | MSI-H | 2026-03-15T05:35:59.036027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381404 | REC_0008863 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.2 | 69 | female | 1 | 38 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.9 | true | MSS | 2026-03-15T05:35:59.036359+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800195 | REC_0008864 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 12.8 | 67 | male | 1 | 10 | 5.3 | 4 | alectinib 600 mg BID | 7 | true | MSS | 2026-03-15T05:35:59.036604+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817656 | REC_0008865 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 16 | 14.2 | 55 | female | 1 | 10 | 5.1 | 6 | alectinib 600 mg BID | 5.9 | false | MSS | 2026-03-15T05:35:59.036851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_881261 | REC_0008866 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.8 | 77 | female | 2 | 19 | 4.9 | 4 | osimertinib 80 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:59.037094+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275191 | REC_0008867 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 14.2 | 62 | male | 0 | 20 | 4.7 | 6 | entrectinib 600 mg daily | 16 | false | MSS | 2026-03-15T05:35:59.037692+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739900 | REC_0008868 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 10.4 | 72 | male | 2 | 12 | 5.3 | 5 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.038122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149863 | REC_0008869 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 7 | 67 | male | 1 | 27 | 4.5 | 5 | carboplatin + paclitaxel + pembrolizumab | 11.6 | false | MSS | 2026-03-15T05:35:59.038430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_252918 | REC_0008870 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 17.1 | 79 | male | 1 | 9 | 5.6 | 2 | osimertinib 80 mg daily | 7.4 | true | MSS | 2026-03-15T05:35:59.038732+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_496703 | REC_0008871 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.7 | 59 | female | 1 | 64 | 5.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 30 | true | MSS | 2026-03-15T05:35:59.039011+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_827122 | REC_0008872 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 5.3 | 70 | female | 1 | 70 | 7.1 | 3 | carboplatin + paclitaxel + pembrolizumab | 4.2 | false | MSS | 2026-03-15T05:35:59.039277+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_480510 | REC_0008873 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 12 | 83 | female | 0 | 27 | 3.5 | 3 | osimertinib 80 mg daily | 12.2 | true | MSI-H | 2026-03-15T05:35:59.039539+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436605 | REC_0008874 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 15.9 | 69 | female | 0 | 13 | 6.3 | 7 | entrectinib 600 mg daily | 9.1 | false | MSI-H | 2026-03-15T05:35:59.039793+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_474361 | REC_0008875 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.5 | 59 | male | 1 | 10 | 6.7 | 8 | entrectinib 600 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.040049+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_495371 | REC_0008876 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 11.6 | 72 | male | 1 | 11 | 3.6 | 4 | alectinib 600 mg BID | 10.7 | false | MSI-H | 2026-03-15T05:35:59.040402+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_763353 | REC_0008877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 3.2 | 78 | female | 0 | 11 | 4.5 | 4 | osimertinib 80 mg daily | 11.1 | true | MSS | 2026-03-15T05:35:59.040696+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352403 | REC_0008878 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 30 | 8.2 | 80 | female | 2 | 12 | 5.9 | 5 | osimertinib 80 mg daily | 9.9 | false | MSS | 2026-03-15T05:35:59.040984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_994274 | REC_0008879 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 8.7 | 50 | male | 0 | 15 | 7.2 | 4 | osimertinib 80 mg daily | 9 | true | MSS | 2026-03-15T05:35:59.041266+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887326 | REC_0008880 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 20 | 9.5 | 87 | male | 1 | 40 | 7.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 17.3 | false | MSS | 2026-03-15T05:35:59.041694+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673467 | REC_0008881 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 21 | 7.3 | 60 | female | 0 | 41 | 4.7 | 7 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:59.042022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_983546 | REC_0008882 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 24 | 9.9 | 69 | female | 1 | 19 | 4.4 | 0 | entrectinib 600 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:59.042321+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_579243 | REC_0008883 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 12.4 | 72 | female | 1 | 19 | 6.4 | 6 | sotorasib 960 mg daily | 13.5 | true | MSI-H | 2026-03-15T05:35:59.042630+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124748 | REC_0008884 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 17.5 | 63 | female | 0 | 15 | 4.3 | 10 | entrectinib 600 mg daily | 15.6 | false | MSS | 2026-03-15T05:35:59.042920+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_149493 | REC_0008885 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 34 | 7.7 | 68 | female | 0 | 13 | 5.1 | 4 | entrectinib 600 mg daily | 10.7 | false | MSS | 2026-03-15T05:35:59.043181+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_839235 | REC_0008886 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 7.3 | 61 | male | 1 | 15 | 5.8 | 2 | osimertinib 80 mg daily | 18.1 | true | MSS | 2026-03-15T05:35:59.043434+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_526656 | REC_0008887 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 2.4 | 72 | female | 2 | 45 | 4 | 4 | carboplatin + paclitaxel + pembrolizumab | 10.3 | true | MSS | 2026-03-15T05:35:59.043673+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_795706 | REC_0008888 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 15.5 | 67 | female | 0 | 16 | 4.5 | 6 | alectinib 600 mg BID | 8.4 | true | MSI-H | 2026-03-15T05:35:59.043916+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_853614 | REC_0008889 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11 | 58 | male | 0 | 20 | 4.8 | 3 | osimertinib 80 mg daily | 11.4 | false | MSS | 2026-03-15T05:35:59.044244+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_113923 | REC_0008890 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 32 | 3.9 | 51 | male | 0 | 40 | 5.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 24.2 | true | MSS | 2026-03-15T05:35:59.044522+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_738280 | REC_0008891 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.5 | 62 | female | 0 | 21 | 6.8 | 1 | osimertinib 80 mg daily | 14.3 | false | MSS | 2026-03-15T05:35:59.044777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546509 | REC_0008892 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 27 | 10.5 | 66 | female | 0 | 13 | 6.2 | 6 | entrectinib 600 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:35:59.045022+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_545441 | REC_0008893 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 12.9 | 76 | female | 1 | 17 | 6.7 | 2 | osimertinib 80 mg daily | 18.8 | false | MSI-H | 2026-03-15T05:35:59.045386+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_501067 | REC_0008894 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 10.7 | 70 | female | 2 | 23 | 5.8 | 2 | entrectinib 600 mg daily | 25.5 | false | MSS | 2026-03-15T05:35:59.045651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330789 | REC_0008895 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 4.7 | 61 | male | 1 | 29 | 8.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.7 | true | MSS | 2026-03-15T05:35:59.045912+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_918603 | REC_0008896 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 9 | 80 | female | 1 | 18 | 3.9 | 2 | alectinib 600 mg BID | 18.2 | false | MSS | 2026-03-15T05:35:59.046178+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859450 | REC_0008897 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 8.5 | 73 | male | 2 | 22 | 6.2 | 2 | entrectinib 600 mg daily | 23.2 | false | MSS | 2026-03-15T05:35:59.046444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_205508 | REC_0008898 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 19 | 9.2 | 63 | female | 0 | 22 | 5.8 | 5 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:59.046708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_915605 | REC_0008899 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 6.3 | 70 | female | 1 | 56 | 6.9 | 6 | carboplatin + paclitaxel + pembrolizumab | 18.9 | false | MSS | 2026-03-15T05:35:59.046975+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_236644 | REC_0008900 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 11.6 | 68 | female | 1 | 7 | 4.3 | 2 | osimertinib 80 mg daily | 17.9 | false | MSS | 2026-03-15T05:35:59.047231+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.